Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Korman, Alan"" wg kryterium: Autor


Wyświetlanie 1-5 z 5
Tytuł :
A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection
Autorzy :
Gardiner, David
Lalezari, Jay
Lawitz, Eric
DiMicco, Michael
Ghalib, Rheem
Reddy, K. Rajender
Chang, Kyong-Mi
Sulkowski, Mark
Marro, Steven O’
Anderson, Jeffrey
He, Bing
Kansra, Vikram
McPhee, Fiona
Wind-Rotolo, Megan
Grasela, Dennis
Selby, Mark
Korman, Alan J.
Lowy, Israel
Pokaż więcej
Temat :
MONOCLONAL antibodies
CHRONIC hepatitis C
APOPTOSIS
DEATH receptors
GENE expression
LIGANDS (Biochemistry)
T cells
PLACEBOS
Źródło :
PLoS ONE; May2013, Vol. 8 Issue 5, p1-11, 11p
Czasopismo naukowe
Tytuł :
TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection.
Autorzy :
Chew GM; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
Fujita T; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.; Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Webb GM; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Burwitz BJ; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Wu HL; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Reed JS; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Hammond KB; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Clayton KL; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
Ishii N; Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Abdel-Mohsen M; Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
Liegler T; Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
Mitchell BI; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
Hecht FM; HIV/AIDS Division, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
Ostrowski M; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
Shikuma CM; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
Hansen SG; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Maurer M; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, United States of America.
Korman AJ; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, United States of America.
Deeks SG; HIV/AIDS Division, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
Sacha JB; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Ndhlovu LC; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
Pokaż więcej
Źródło :
PLoS pathogens [PLoS Pathog] 2016 Jan 07; Vol. 12 (1), pp. e1005349. Date of Electronic Publication: 2016 Jan 07 (Print Publication: 2016).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
CD4-Positive T-Lymphocytes/*immunology
CD8-Positive T-Lymphocytes/*immunology
HIV Infections/*immunology
Receptors, Immunologic/*immunology
Animals ; B7-H1 Antigen/immunology ; Cell Separation ; DNA, Viral/analysis ; Disease Progression ; Flow Cytometry ; Humans ; Lymphocyte Activation/immunology ; Macaca mulatta ; RNA, Viral/analysis ; Simian Acquired Immunodeficiency Syndrome/immunology
Czasopismo naukowe
Tytuł :
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Autorzy :
Selby MJ; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Engelhardt JJ; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Johnston RJ; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Lu LS; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Han M; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Thudium K; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Yao D; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Quigley M; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Valle J; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Wang C; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Chen B; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Cardarelli PM; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Blanset D; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Korman AJ; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2016 Sep 09; Vol. 11 (9), pp. e0161779. Date of Electronic Publication: 2016 Sep 09 (Print Publication: 2016).
Typ publikacji :
Journal Article
MeSH Terms :
Immunotherapy*
Antibodies, Monoclonal/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Melanoma/*drug therapy
Animals ; Antibodies, Monoclonal/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/metabolism ; Cell Line, Tumor ; Cells, Cultured ; Colorectal Neoplasms/metabolism ; Colorectal Neoplasms/therapy ; Combined Modality Therapy ; Disease Models, Animal ; Female ; Humans ; Ipilimumab ; Lymphocytes/immunology ; Lymphocytes/metabolism ; Macaca fascicularis ; Melanoma/metabolism ; Melanoma/therapy ; Mice ; Mice, Inbred C57BL ; Nivolumab ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/metabolism ; T-Lymphocytes, Regulatory/metabolism
Czasopismo naukowe
Tytuł :
Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Autorzy :
Selby MJ
Engelhardt JJ
Johnston RJ
Lu LS
Han M
Thudium K
Yao D
Quigley M
Valle J
Wang C
Chen B
Cardarelli PM
Blanset D
Korman AJ
Pokaż więcej
Źródło :
PloS one [PLoS One] 2016 Nov 18; Vol. 11 (11), pp. e0167251. Date of Electronic Publication: 2016 Nov 18 (Print Publication: 2016).
Typ publikacji :
Published Erratum
Tytuł :
An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients.
Autorzy :
Colston E; Innovative Medicines Development, Bristol-Myers Squibb, Princeton, New Jersey, United States of America.
Grasela D; Innovative Medicines Development, Bristol-Myers Squibb, Princeton, New Jersey, United States of America.
Gardiner D; Infectious Diseases Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America.
Bucy RP; Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Vakkalagadda B; Clinical Pharmacology and Pharmacometrics, Bristol-Myers Squibb, Hopewell, New Jersey, United States of America.
Korman AJ; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, United States of America.
Lowy I; Translational Science and Clinical Oncology, Regeneron Pharmaceuticals, Tarrytown, New York, United States of America.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2018 Jun 07; Vol. 13 (6), pp. e0198158. Date of Electronic Publication: 2018 Jun 07 (Print Publication: 2018).
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
CTLA-4 Antigen/*immunology
HIV Infections/*drug therapy
HIV-1/*immunology
Ipilimumab/*administration & dosage
Viremia/*drug therapy
Adult ; CD4 Lymphocyte Count ; CTLA-4 Antigen/antagonists & inhibitors ; Dose-Response Relationship, Drug ; Female ; HIV Infections/immunology ; HIV Infections/metabolism ; HIV Infections/virology ; Humans ; Ipilimumab/adverse effects ; Ipilimumab/pharmacokinetics ; Male ; Maximum Tolerated Dose ; Middle Aged ; RNA, Viral/blood ; Viremia/immunology ; Viremia/metabolism
Czasopismo naukowe
    Wyświetlanie 1-5 z 5

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies